IHT Wealth Management LLC lifted its position in Regenxbio Inc (NASDAQ:RGNX) by 36.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,362 shares of the biotechnology company’s stock after buying an additional 2,770 shares during the quarter. IHT Wealth Management LLC’s holdings in Regenxbio were worth $369,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in RGNX. Oregon Public Employees Retirement Fund grew its position in Regenxbio by 4.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 12,158 shares of the biotechnology company’s stock worth $625,000 after buying an additional 498 shares in the last quarter. NEXT Financial Group Inc bought a new stake in shares of Regenxbio during the 2nd quarter valued at about $69,000. Arizona State Retirement System boosted its position in shares of Regenxbio by 1.2% during the 2nd quarter. Arizona State Retirement System now owns 47,739 shares of the biotechnology company’s stock valued at $2,452,000 after acquiring an additional 547 shares during the last quarter. Botty Investors LLC boosted its position in shares of Regenxbio by 2.7% during the 2nd quarter. Botty Investors LLC now owns 247,337 shares of the biotechnology company’s stock valued at $12,706,000 after acquiring an additional 6,600 shares during the last quarter. Finally, Virginia Retirement Systems ET AL purchased a new position in shares of Regenxbio during the second quarter worth about $216,000. Institutional investors own 78.44% of the company’s stock.
RGNX opened at $40.68 on Tuesday. The company has a current ratio of 11.49, a quick ratio of 11.49 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.46 billion, a P/E ratio of 17.09 and a beta of 0.86. The stock has a 50-day moving average price of $38.54 and a 200-day moving average price of $41.54. Regenxbio Inc has a 12-month low of $30.38 and a 12-month high of $63.21.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.03). The firm had revenue of $14.70 million for the quarter, compared to analysts’ expectations of $7.46 million. Regenxbio had a negative net margin of 99.57% and a negative return on equity of 18.74%. The business’s quarterly revenue was up 177.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.56) earnings per share. On average, equities research analysts predict that Regenxbio Inc will post -2.8 EPS for the current year.
In other news, CEO Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $39.75, for a total value of $397,500.00. Following the completion of the sale, the chief executive officer now directly owns 251,000 shares in the company, valued at approximately $9,977,250. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Patrick J. Christmas sold 5,486 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $42.00, for a total transaction of $230,412.00. Following the completion of the sale, the senior vice president now owns 8,058 shares of the company’s stock, valued at $338,436. The disclosure for this sale can be found here. 13.80% of the stock is owned by corporate insiders.
A number of equities research analysts recently weighed in on the stock. Morgan Stanley lowered their target price on shares of Regenxbio from $85.00 to $59.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Zacks Investment Research lowered shares of Regenxbio from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Svb Leerink raised shares of Regenxbio from an “underperform” rating to a “market perform” rating and cut their price target for the stock from $38.00 to $37.00 in a research note on Tuesday, August 20th. Chardan Capital set a $150.00 price target on shares of Regenxbio and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, Evercore ISI restated a “buy” rating and set a $65.00 price objective on shares of Regenxbio in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $76.71.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Article: Why is the LIBOR significant?
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.